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Summary
Introduction: the cardiovascular autonomic neuropathy increases the risk of silent myocardial 
ischemia and intraoperative cardiovascular liability. Additionally, from 27 to 56% of the patients with 
this diagnosis dies in the following 5-10 years. Cardiovascular autonomic neuropathy is detected by 
means of an electrocardiograph registration that monitors changes in heart rate induced by different 
stimulus. The autonomic symptom profile evaluates symptoms of autonomic function but it was not 
considered their reliability and validity with cardiovascular autonomic neuropathy diagnosis. It was 
carried out a study to determine the validity and reliability of the autonomic symptoms profile in the 
diagnosis of cardiovascular autonomic neuropathy. Materials and methods: from june to december of 
2005, 103 participants responded the questionnaire spanish version twice. Then, 52 participants took 
the autonomic function test; the validity of the content of the questionnaire was evaluated by the 
cronbach’s alpha and the reliability test-retest by intraclass correlation coefficient. It was considered 
the prevalence, sensibility and specificity of the score obtained with the presence of cardiovascular 
autonomic neuropathy. Results: The validity of content was good (cronbach’s alpha >0,7). The reliability 
of the total score questionnaire was poor intraclass correlation coefficient (ICC 0,36 0,06-0,6) and the 
discriminative capacity of the questionnaire for the detection of cardiovascular autonomic neuropathy 
was bad for anyone of the selected court points Receiver operating curve (ROC area 0,5). Conclusions: 
the questionnaire evaluates the symptoms of autonomous function consistently; it has a low reliability 
and poor discriminative capacity to define the presence of cardiovascular autonomic neuropathy. (MÉD.
UIS. 2009;22(2):138-45).
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IntroductIon
The Cardiovascular Autonomic Neuropathy 
(CAN) is characterized by the deterioration of small 
myelinized and unmyelinized autonomic fibers that 
innerve the heart, blood vessels and different organs 
in the gastrointestinal and urogenital systems1. These 
complications are frequent in diabetes mellitus and the 
risk both silent myocardial ischemic and intraoperatory 
liability are higher in this population. Additionally, from 
27 to 56% of diabetics with CAN dies in the following 
5-10 years1,2. The prevalence of CAN is from 7 to 27%, 
it depends on the population studied and diagnostic 
criteria used1. The CAN diagnosis is made with a 
continuous electrocardiograph registry that detects the 
variability of heart rate after different stimulus (e.g. deep 
breathing, lying to standing). These measurements are 
the most useful in these people3-5. In spite of objectivity 
and standardized methods, the principal disadvantage 
is the necessity of specialized laboratory, accessibility 
and cost in developing countries.
 
The autonomic symptom profile is a questionnaire 
with 74 questions created previously and evaluated in 
face and content validity6. In that study, the authors 
showed that scores in patients with autonomic 
neuropathy were higher than healthy ones and patients 
with other neuropathies6. However, they did not 
evaluate the reliability test-retest, internal consistency 
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and criteria validity with objectives measurements 
of autonomic function. It was carried out a study to 
determine the validity and reliability of the profile of 
autonomous symptoms in the CAN diagnosis.
MaterIals and Methods
Participants between 15 to 65 years old, with 
diagnosis of diabetes mellitus, assistants to program 
of chronic disease in a clinical center of Bucaramanga, 
Colombia were selected. Participants with deafness 
or mental incapacity for answer the questionnaire 
were excluded. The protocol was approved by ethical 
committee of the Universidad Industrial de Santander. 
All patients gave their consent in order to participate 
in the study.
The autonomic symptom profile was translated 
and retro-translated from English to Spanish by two 
translators with good understanding of English. The 
authors had consensus and there was no difference 
in meaning or sense with the original version.
All participants had an interview with a nurse 
previously trained, who applied the instrument in 
a standardized way. The second measurement was 
realized in similar conditions but by telephone. The 
questionnaire was graded according to the author’s 
test. The total score was 0-200 for men and 0-170 for 
women.
The autonomic function test was realized from 
10:00 a.m to 4:00 p.m. in an isolated room with 
temperature approximately of 22 °C. Antihypertensive 
medicines or other treatment were no suspended due 
to the usual condition of the patients. By means of an 
electrocardiography register and used the Wincprs 
version. 1,1597 the cardiac cycle was measured in 
three conditions, rest breathing, deep breathing (6 
cycles/min) and lying to standing. The deep breathing 
was controlled by a visual timer that allow to train 
during a minute before the definitively register. There 
were obtained the 30/15 ratio, E/I ratio, delta E-I 
ratio, mean RR and other measurements of heart rate 
variability. The signal’s evaluators were masked to the 
scores obtained in the questionnaire and the double 
reading. There were two readings in the autonomic 
function measurements. The evaluators had two years 
and three months of experience respectively. Cutoffs 
default American population data were taken for 
standardization by Ewing, Ziegler and Gerritsen, et al. 
(Table 1)5,8,9.
saMple sIze
It was calculated a sample size of 102 participants 
to detect a prevalence of CAN about 22% with an 
error in the estimation of 12% and alpha and beta 
error of 5% and 20% respectively. The study took 50 
participants to apply objective autonomic test and 
maintained minimum 10 participants in the marginal 
ones the table of two by two with the prevalence 
estimated10. For the reliability study it was estimated 
a intraclass correlation coefficient between 0,6–0,8 in 
order to reject the null hypothesis of none agreement 
between both measurements. This was an alpha error 
5% and power of 80%. In agreement with Kraemer11 it 
was calculated a delta in the following form: ∆= (0,6-
0,8)/(1-(0,6*0,8))=0,38. This value was searched in the 
master table in the book and it was selected with the 
power and alpha wished (n = 41 +1).
statIstIcal analysIs
The content validity was evaluated with cronbach’s 
alpha and excluded items that improved or maintained 
the internal con-sistency among 0,7 to 0,9.12 The 
agreement was calculated with the intraclass correlation 
coefficient and their confidence intervals of 95%13. For 
criteria validity, the measurement of autonomic function 
was compared with the best reliability and cut-points 
publicated and the total score. Initially it was calculated 
the level of the test (Q), the predictive values (PPV, 
NPV) and confidence intervals directly for each ten 
points of the total score. In according with the sampling, 
conditional probability with Bayesian approximation 
was used to calculate sensibility (S), specificity (E) and 
prevalence (P)10. Then, a ROC curve was constructed. 
The statistical analysis was done in the STATA 8.014.
autonoMIc syMptoM profIle
The mean total score in the autonomic symptom 
profile was 22 points RIQ (8,75-33). The secretomotor 
symptoms was the highest score compared with the 
Measures Cutoffsw
E/I ratio < 1,25*
30/15 ratio < 1*
delta E/I
20-24 years <136 ms
25-29 years <127,4 ms
30-34 years <119,4 ms
35-39 years <111,9 ms
40-44 years <104,8 ms
45-44 years < 98,2 ms
50-54 years <86,2 ms
56-60 years < 80,8 ms
61-65 years < 75,7 ms
Table 1. Cutoffs of autonomic measurements.
abbreviations: *No units, ms: milliseconds
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other dominions, mean 3 points RIQ (1,5-6); followed 
by the upheavals of the sleep, mean 1,5 points RIQ 
(0-2,3). In the sexual activity symptoms the erectile 
dysfunction had a high score in this group, mean 
8,0 points RIQ (2-9). All participants referred some 
symptoms; it was found that the vasomotor symptoms 
were the most frequent, followed by sleep and pupil 
alterations. Additionally, the sub-scale that measure 
the presence of previously symptoms related with 
concentration problems, nausea, diarrhea, loss of 
appetite or epigastric pain was also high. Only domains 
of orthostatism, syncope, vasomotor symptoms, 
secretomotor symptoms, diarrhea, constipation and 
pupil alteration showed internal consistency among 
0,7 to 0,9, cut points recommended to consider good 
internal consistency (Table 2).
results
From june to december 2005, 103 persons were 
included in the study. The mean age was 57 years RIQ 
(52-62 years), 38% were men. The majorities were 
diabetic type 2 (69%), received oral treatment (75%) 
and up to 50% has been diagnosed more than six years 
before stic RIQ (6-10 years) (Table 3).
relIabIlIty of autonoMIc Measures
Reliability of autonomic symptom profile was low 
because almost all domains had intraclass correlation 
coefficient (ICC) lowers than 0,7; except the questions 
about erectile dysfunction ICC 0,75 (0,58-0,86). Probably 
Variable P50 (RIQ) % >0 (IC95%)
alpha 
cronbach
ICC (IC 95%)
Total score* 22,1 (8.75-33) 100 (42-63) 0,85 0,36 (0,06-0,6)
Orthostatic intolerance 1,3 (0-20) 52 (42-62) 0,85 0,28 (0,01-0,54)
Syncope 0 (0-0) 12 (6-19) 0,79 ¶ 0,41 (0,12-0,63)
Vasomotor 0 (0-0) 19 (12-28) 0,79 0,46 (0,18-0,67)
Secretomotor 3 (1,5-6,0) 99 (94-99) 0,76 0,18 (-0,12-0,46)
Gastroparesis 0 (0.0-1,7) 32 (23-42) 0.42 0,21 (-0,09-0,49)
Diarrhea 0 (0-0) 21 (14-30) 0,73¦ 0,26 (-0,52-0,04)
Constipation 0 (0-1,5) 39 (29-49) 0,72 0,35 (0,05-0,59)
Slowed down vesical 
evacuating
0 (0,0-2,0) 39 (29-49) 0,49 0,23 (-0,07-0,5)
Pupillomotor reflex 
alterations
0,5 (0,0-1,5) 65 (55-74) 0,73 0,51 (0,24-0,7)
Sleep 1,5 (0,0-2,3) 75 (65-83) 0,23 0,17 (-0,14-0,45)
Eréctil dysfunction † 8 (2-9) 27 (19-37) 0,67 0,75 (0,58-0,86)
Ejaculation problems † 0 (0-0) 5 (2-10) 0,63 -0.1 (-0,1-0,39)
Validity scale
Psychosomatic 0 (0,0-0,0) 11 (5-18) 0,52 0 (-0,3-30)
Understatement index 8,3 (4,9-8,3) 98 (93-99) 0,67 0,15 (-0,15-0,44)
Table 2. Reliability test-retest, internal consistency autonomic symptom profile.
Abbreviations: % >0= Percent of people with scores higher than cero. *Total score: men 0-200; women 0-170. 
† Only men. ‡ Only questions 10 y 11. ¶ excluded question 47.
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these symptoms were remembered easier and with 
lowest variation on the time (Table 1). The measurements 
obtained of the autonomic function test were reliable 
among evaluators, the most reliable were the Pnn50 and 
the delta E-I ICC 0.98 (0,97-0,99) (Table 4).
Table 3. Characteristics participants included. 
Characteristics
Participants 
N=103
Demographic
Age years, p50 (RIQ) 57 (52-62)
Gender, (male) n (%) 39 (38)
Socio-economic level
Low 0-2, n (%) 46 (45)
Middle / high 3-6, n (%) 56 (55)
Diabetes mellitus
Type 1, n (%) 20 (19)
Type 2, n (%) 71 (69)
Non Classify, n (%) 12 (12)
Diagnostic time years, p50 (RIQ) 6 (6-10)
Fasting glucose mg/dl, p50 (RIQ)
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(113-180)
Treatment 
Insulin, n (%) 23 (22)
Oral medicines, n (%) 76 (74)
Exclusive diet / nothing, n (%) 4 (4)
Comorbidities
Hypertension, n (%) 40 (39)
Antecedent of high cholesterol, n (%) 31 (30)
Antecedent of low thyroid hormone, 
n (%)
4 (4)
Previous stroke, n(%) 1 (1)
Previous myocardial infarction, n(%) 1 (1)
None, n (%) 26 (25)
Physical exam
Weight kg, mean (SD) 69 (13.0)
Height mts., mean (SD) 1.6 (0.08)
Body mass index, mean (SD) 27 (4.37)
Cardiac pulse, mean (SD) 73 (10)
Systolic blood pressure (mmHG), 
mean (SD) 119 (14)
Abbreviations: p50: percentile 50, p25: percentile 25, p75: 
percentile 75, (SD): standard deviation.
Table 4. Reliability of measures of autonomic function test. 
Factor
Evaluator 1 
Mean (SD)
Evaluator 2 
Mean (SD)
ICC (IC 95%)
Mean R-R, 
ms
788 (95,3) 791 (91,3) 0,97 (0,95 – 0,98)
Ratio 
30/15
1,07 (0,10) 1,08 (0,13) 0,63 (0,42 – 0,77)
Ratio E/I 1,15 (0,01) 1,16 (0,01) 0,97 (0,95 – 0,98)
Delta E-I, 
ms
118 (66,4) 122 (69,9) 0,98 (0,97 – 0,99)
Minimum, 
ms
707 (79,5) 711 (98,3) 0,71 (0,55 – 0,83)
Maximum, 
ms
880 (119) 864 (107) 0,91 (0,85 – 0,94)
CV 2,3 (1,07) 2,2 (1,19) 0,89 (0,83 – 0,94)
RMSSD 18 ( 9,9) 18 (11) 0,92 (0,86 – 0,95)
Pnn 
50, ms
2,8 
(6,21)
2,8 
(6,73)
0,98 (0,97 – 
0,99)
crIterIa valIdIty
The prevalence of CAN founded in this study was 
43% in the delta e-i, 28% in mean r-r and 85% in e/i 
ratio. The 72% of participants obtained more than 
10 points in the total score (q), there was not a cut-
off point with both good specificity and sensibility 
and the discriminative capacity of the total score for 
can diagnosis was in the random line in spite of the 
measurement considered (figure 1). the score with the 
better sensibility was >10 points (s= 63%) and >50 
points for specificity and efficiency (e=91%; eff= 
60%). the best (ppv) in the cut off > 20 points was 
for e/i ratio (Table 5).
dIscussIon
The dysfunction of the autonomic nervous 
system is a serious problem in diabetic patients. The 
Abbreviations: mean R-R intervals, Ratio 30/15, E/l: 
Expiration /Inspiration ratio. Delta E-l diferences of the 
intervals R-R in Expiration and inspiration, Minimum: Mean 
of R-R intervals minimum. Maximum: Mean of R-R intervals 
maximum. CV: Varation coefficient, RMSSD: The sum of 
squares of mean differencess squares among R-R intervals. 
Pnn 50: Percent of R-R intrvals that differ more than 50ms. 
Ms milliseconds.
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Figure 1. Area under the curve of total score and three measures of autonomic function.
Autonomic 
symptom profile
Delta E/I Mean R-R E/I ratio
Positive Negative Positive Negative Positive Negative
> 20 11 12 6 16 20 2
< 20 10 17 8 20 22 6
Total 21 29 14 36 42 8
P (%) 43 28 85
Q (%) 53 (43-63) 53 (43-63) 53 (43-63)
S (%) 59 52 56 
E (%) 51 47 56
PPV (%) 44 (31-57) 25 (16-41) 84 (74-94)
NPV (%) 63 (49-67) 70 (57-84) 22 (10-34)
A= delta E-I; B= mean R-R; C= E/I ratio.
Table 5. Validity criteria of autonomic symptom profile and autonomic function test.
Abbreviations: Mean R-R: Mean of R-R intervals, Ratio 30/15, E/I: Expiration/Inspiration ratio. P: Prevalence; Q: level of 
the test; S: sensibility; E: Specificity; PPV: positive predictive value; NPV: negative predictive value; CI 95%: confidence 
interval 95%.
A B
C
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In previous studies the autonomic symptoms were 
evaluated using other standardized instruments that 
ask about the frequency of symptoms in the last 30 
days. The Diabetes control and complications trial 
(DCCT study (diabetic 26 to 34 years), used this type 
of instrument and the most frequent symptom was 
postural hypotension (3,9%) followed by hypoglycemic 
unadvertised (8,7%)23. Ziegler and Cols. found 
postural dizziness (11%) and erectile dysfunction as 
more frequent (19%)24. It was founded the erectile 
dysfunction with the highest score (8 points). 
Low and Cols. applied the autonomic symptom 
profile in a study and the results were similar 
than the obtained in this study. For example, the 
vasomotor symptoms they found mean 0,98 points 
(SD=1,98) and in the evaluated people the mean was 
0,86 (SD=2)25. However, this shows the necessity to 
modify the scale, because it probably does not reflect 
the state of the patients.
In the other side, the reliability of the autonomic 
symptoms was poor showing the variability of its 
occurrence. This situation reduces the reliability of 
the measurement and induces a misclassification. In 
epidemiological research it is recognized that a no 
reliable instrument reduces the discriminative capacity 
and increase a sample size of the studies26.
The measurements of objective autonomic 
measures were a good reliability among two evaluators, 
independent of their experience. This guarantees the 
precision of measures for diagnosis in CAN but do not 
guarantee the presence of the disease. This was not 
a scope of this study because the evaluation of real 
autonomic function does not have a gold standard. 
However, it is accepted with expert consensus that the 
autonomic function must be evaluated with the Ewing 
tests. The Experts recommend at first line the delta E-I 
in diabetic people4.
The criteria validity of autonomic symptom profile 
was analyzed with a prospective sample, this had an 
advantage in saving money and time because it wasn’t 
needed to do the objective measures in all sample. This 
methodology is a simple application of Bayesian theory 
used in evaluating medical test. Confidence intervals 
for prevalence, sensibility and specificity weren’t 
calculated because they did not found directly unlike 
the predictive values10.
The autonomic symptom profiles does not only 
evaluate cardiovascular symptoms and one of the 
limitations is doing measurements of autonomic 
function in other organs. However, the study was 
interested in evaluate autonomic symptom profile in the 
detection of CAN mainly. In the other side, it’s  shown 
how a reliability of the measures between evaluators 
is enough for use in clinical practice and research. 
cardiovascular autonomic neuropathy is the most 
important autonomic dysfunction for its implication 
in the increase of mortality rate2, therefore the 
importance of detecting and quantifying the symptoms 
of autonomic dysfunction. The patients with CAN 
present episodes of silent myocardial ischemia that 
can evolve easily into a myocardial infarction15-17, 
also presents intraoperative cardiovascular lability 
representing morbidity and mortality two to three 
times higher compared to non-diabetics18. Burgos and 
cols. showed that the induction of anesthesia caused a 
large decline in heart rate and blood pressure in these 
patients, and the administration of vasopressors is 
most frequently used19, Kitamura and cols. found an 
association between severe intraoperative hypothermia 
and CAN, which would generate a decrease in the 
metabolism of the drug and problems in the healing 
of the wound20 and Sobotka and cols. showed that 
diabetic patients with CAN have reduced the hypoxic 
ventilatory response induced21. Therefore, the 
investigation of CAN in all diabetics to be subjected to 
surgery is essential to identify patients at risk and plan 
carefully anesthetic treatment for the patient.
Being important the recognition of autonomic 
symptoms, Suarez and cols. describe a questionnaire 
(Autonomic symptom profile) that measures a wide 
range of symptoms related to different aspects of 
autonomic disorders in grouping domains that provide 
a scoring system called the Composite Autonomic 
Symptom Scale (COMPASS)2. The questionnaire has 
an internal validity demonstrated to compare the 
results with the Symptom Composite Autonomic 
Scoring Scale (CASS)22, derived from a group of non-
invasive tests sensitive, specific, reproducible and 
standardized that detect and quantify symptoms of 
autonomic dysfunction, having a good correlation 
(p <0,001).
In the present study, the psychometric 
characteristics of autonomic symptom profile 
were analyzed since different aspects such as 
reliability, internal consistency and criteria validity 
in front of objectives measurements of autonomic 
cardiovascular function. 
The tests were evaluated in diabetic people with 
a long term evolution of the disease in whom the 
CAN have high prevalence and the performance 
of the test could be best way of diagnose the 
condition10. However, it could not be demonstrated 
that the presence of autonomic disease is related 
with the presence of autonomic symptoms. This 
results are explained by the chronic condition of the 
disease, since in other methodological reports have 
been detected problems to apply questionnaires in 
patients with this type of diseases12. This participants 
can overestimate or underestimate their symptoms and 
to lose the discriminative capacity of the instrument12.
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Additionally, autonomic symptom profile could be 
modified with questions about of acute autonomic 
symptoms related with diseases like sepsis or systemic 
inflammatory response syndrome where autonomic 
system is a modulator in cardiovascular answer 
mediated by endotoxin27.  
The results of this study does not assign to a systematic 
bias in patients selection because these were included 
in a consecutive and the performance of autonomic 
measures was masking of the score of autonomic 
symptom profile. The patients with measurements 
without interpretation were not excluded11.
In clinical practice, this questionnaire can be 
used to identify diabetic patients with autonomic 
neuropathy and also to diagnose the disease early 
to treat diabetes more intensively because only the 
approach and maintenance of near glucose blood 
levels are the most effective way to prevent the 
cardiovascular autonomic neuropathy in the diabetic 
patients23,28,29.
conclusIon
The autonomic symptom profile has a good 
internal consistency, poor reliability test-retest and did 
not have a discriminative capacity for the diagnosis of 
autonomic cardiovascular function. The test identifies 
diabetic patients who have symptoms of cardiovascular 
autonomic neuropathy of those who do not have. This 
is important in clinical practice for its implication 
in the increase of the mortality rate, allowing the 
selection of diabetic patients in which diabetes should 
be treated more intensively. Another important feature 
of the test is the potential ability to recognize clinically 
important changes, such as improvement or worsening 
of symptoms, which may translate into scores useful 
to monitor the progression of disease and to evaluate 
the response to treatment but further testing is needed 
to assess it. Our new research proposal is to establish 
the frequency of the autonomic neuropathy symptoms 
and evaluate their association with the duration of 
diabetes and socioeconomic and therapeutic variables, 
because this information is unknown in the colombian 
and latin-american population. It’s also interesting 
the investigation of the presence of acute autonomic 
symptoms related with sepsis or SIRS, since the topic 
has not been explored so far.
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resuMen
Validez y confiabilidad de la prueba de síntomas autonómicos.
Introducción: la neuropatía autonómica cardiovascular incrementa el 
riesgo de isquemia miocárdica silente y de inestabilidad cardiovascular 
intraoperatoria. Además, el 27 al 56% de los pacientes con este 
diagnóstico muere en los siguientes 5 – 10 años. La neuropatía 
autonómica cardiovascular es detectada por medio de un registro 
electrocardiográfico que monitorea cambios en la frecuencia cardíaca 
inducida por diferentes estímulos. El perfil de síntomas autonómicos 
es un test que evalúa síntomas de función autonómica pero no se ha 
considerado su confiabilidad y validez con el diagnóstico de neuropatía 
autonómica cardiovascular. Se realizó un estudio para determinar la 
validez y confiabilidad del test de perfil de síntomas autonómicos en el 
diagnóstico de la neuropatía autonómica cardiovascular. Materiales y 
métodos: de junio a diciembre de 2005, 103 participantes respondieron 
la versión en español del cuestionario de perfil de síntomas autonómicos 
en dos oportunidades. Después, 52 participantes tomaron la prueba 
de función autonómica, la validez del contenido de cuestionario 
fue evaluada por medio del alfa de cronbach y la confiabilidad 
test-retest por medio del coeficiente de correlación intraclase. Se 
consideró la prevalencia, sensibilidad y especificidad del puntaje 
obtenido con la presencia de neuropatía autonómica cardiovascular. 
Resultados: la validez del contenido fue buena (alfa de cronbach 
>0,7). La confiabilidad del resultado total del cuestionario fue pobre 
coeficiente de correlación intraclase (ICC 0,36 0,06-0,6) y la capacidad 
discriminativa del cuestionario para la detección de neuropatía 
autonómica cardiovascular fue mala para cualquiera de los puntos 
de corte seleccionados (Área ROC 0.5). Conclusiones: el cuestionario 
evalúa los síntomas de función autonómica sistemáticamente; tiene 
una baja confiabilidad y pobre capacidad discriminativa para definir la 
presencia de síntomas de neuropatía autonómica cardiovascular. (MED.
UIS. 2009;22(2):138-45).
Palabras clave: Función autonómica. Confiabilidad. Validez. Función 
autonómica cardiovascular. Neuropatía. Diabetes mellitus.
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